PMID- 15454112
OWN - NLM
STAT- MEDLINE
DCOM- 20050815
LR  - 20171116
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 4
IP  - 13
DP  - 2004 Dec 15
TI  - Differential expression of dendritic cell markers by all-trans retinoic acid on 
      human acute promyelocytic leukemic cell line.
PG  - 1587-601
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) for 
      naive T cells and play an important role in cancer immunology. All-trans retinoic 
      acid (ATRA) is known to be a differentiating agent in the treatment of acute 
      promyelocytic leukemia (APL). In this study, we investigated whether ATRA can 
      differentiate the retinoic acid (RA)-sensitive promyelocytic leukemic cell line, 
      NB4, to DC-like cells and whether these differentiated cells can activate T 
      cells. NB4 cells were differentiated to myeloid cells by 4, 6, and 8 days of ATRA 
      treatment. NB4 cells up-regulated markers found in DCs, including HLA-DR, 
      costimulatory molecules (CD80 and CD86), adhesion molecules (CD40), and chemokine 
      receptors (CCR6) when cultured for 8 days in the presence of 1 microM ATRA. 
      Upregulation of CD83 was also detected on the surface of ATRA-treated NB4 cells 
      versus untreated cells. The addition of cytokines alone, such as GM-CSF or CD40 
      ligand, did not affect the expression of CD83 in untreated NB4 cells but they 
      up-regulated CD83 in ATRA-treated cells. CD11b was coexpressed with CD80, CD83, 
      and CD86 in ATRA-treated NB4 cells. In a functional assay, ATRA-treated NB4 cells 
      stimulated T cell proliferation when challenged with Staphylococcus enterotoxin 
      B. These results suggest that the differentiation of NB4 cells by ATRA causes the 
      cells to express DC markers, and that ATRA-differentiated NB4 cells are able to 
      present antigens to T cells.
FAU - Park, Hae-Young
AU  - Park HY
AD  - Medical Research Center for Cancer Molecular Therapy, College of Medicine, Dong-A 
      University, Busan 602-714, Korea.
FAU - Park, Ji-Yeon
AU  - Park JY
FAU - Kim, Ja-Woong
AU  - Kim JW
FAU - Lee, Min-Jung
AU  - Lee MJ
FAU - Jang, Min-Jung
AU  - Jang MJ
FAU - Lee, Sun-Young
AU  - Lee SY
FAU - Baek, Dae-Won
AU  - Baek DW
FAU - Park, Yeong-Min
AU  - Park YM
FAU - Lee, Sang-Wha
AU  - Lee SW
FAU - Yoon, Sik
AU  - Yoon S
FAU - Bae, Yoe-Sik
AU  - Bae YS
FAU - Kwak, Jong-Young
AU  - Kwak JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Surface)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD11b Antigen)
RN  - 0 (CD86 protein, human)
RN  - 0 (Cytokines)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 7)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Antigen-Presenting Cells/drug effects/immunology/metabolism
MH  - Antigens, CD/genetics/metabolism
MH  - Antigens, Surface/drug effects/genetics/metabolism
MH  - B7-1 Antigen/genetics/metabolism
MH  - B7-2 Antigen
MH  - Blotting, Western/methods
MH  - CD11b Antigen/drug effects/genetics
MH  - *Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cytokines/classification/pharmacology
MH  - Dendritic Cells/*drug effects/immunology/metabolism
MH  - Flow Cytometry/methods
MH  - Humans
MH  - Korea
MH  - Leukemia, Promyelocytic, Acute/*pathology
MH  - Lymphocyte Activation/drug effects/immunology
MH  - Membrane Glycoproteins/genetics/metabolism
MH  - Phagocytosis/drug effects/physiology
MH  - RNA, Messenger/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - T-Lymphocytes/drug effects/immunology
MH  - Tretinoin/*pharmacology
MH  - Tumor Necrosis Factor Receptor Superfamily, Member 
      7/immunology/metabolism/pharmacology
MH  - Up-Regulation/*drug effects/*genetics
EDAT- 2004/09/30 05:00
MHDA- 2005/08/16 09:00
CRDT- 2004/09/30 05:00
PHST- 2004/02/16 00:00 [received]
PHST- 2004/03/15 00:00 [revised]
PHST- 2004/07/06 00:00 [accepted]
PHST- 2004/09/30 05:00 [pubmed]
PHST- 2005/08/16 09:00 [medline]
PHST- 2004/09/30 05:00 [entrez]
AID - S1567-5769(04)00220-6 [pii]
AID - 10.1016/j.intimp.2004.07.010 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2004 Dec 15;4(13):1587-601. doi: 
      10.1016/j.intimp.2004.07.010.